How much is the latest price of a box of Sotolasib (AMG510)?

The development of sotoracib (AMG510) is an oral anticancer drug that represents a major advance in the field of oncology treatment. As a targeted therapy, sotoracib was developed to target the KRAS G12C mutation, a common cancer-related mutation. KRAS G12Cmutations are widely present in a variety of cancers, especially non-small cell lung cancer (NSCLC).

Currently, sotoracib is not available in China, so domestic patients cannot purchase it directly. But they can choose to obtain the drug overseas. In the overseas market, sotorasibu exists in two forms: original drug and generic drug.

Original drugs are mainly divided into European versions and Hong Kong versions. Their prices are quite expensive, ranging from tens of thousands to tens of thousands. In contrast, the prices of generic drugs that have been launched abroad are more affordable. Take generic drugs in Laos as an example. Recently, the prices of generic drugs produced by Lao Lucius and Lao Daxiong companies have been significantly reduced, and now only cost more than one thousand to two thousand yuan. This undoubtedly relieves a lot of financial pressure on patients who need such drugs.

It is worth mentioning that whether they are original drugs or generic drugs, their drug ingredients are basically the same, which means that patients can make more appropriate choices based on their financial situation when choosing drugs.

KRAS is a cancer-promoting gene, and its abnormal activation is closely related to the occurrence and development of tumors. In the KRAS G12C mutation, mutations in this gene lead to changes in the protein structure, allowing cancer cells to continue to proliferate and evade the body's normal growth control mechanisms. The mechanism of action of sotorasiib is to inhibit the activity of KRAS G12C protein and block the internal signal transduction pathway of cancer cells, thus effectively inhibiting the growth and spread of tumors.

Clinical trial data show that sotorasiib has demonstrated significant efficacy in the treatment of patients with advanced or metastatic NSCLC harboring KRAS G12C mutations. This result has attracted widespread attention and has been approved for clinical use in some countries. This means a new treatment option and brings hope to patients who have previously been difficult to treat.

However, although the emergence of sotoracib has brought new hope to cancer patients, its therapeutic effect still needs to be further verified in wider clinical practice. In addition, like other drugs, sotorasiib may have some side effects and safety considerations, so its use requires close monitoring and careful management.